title: The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
abstract: Cardiac hypertrophy and failure are accompanied by a reprogramming of gene expression that involves transcription factors and chromatin remodeling enzymes. Little is known about the roles of histone methylation and demethylation in this process. To understand the role of JMJD2A, a histone trimethyl demethylase, in cardiac hypertrophy, we generated mouse lines with heart-specific Jmjd2a deletion (hKO) and overexpression (Jmjd2a-Tg). Jmjd2a hKO and Jmjd2a-Tg mice had no overt baseline phenotype, but did demonstrate altered responses to cardiac stresses. While inactivation of Jmjd2a resulted in an attenuated hypertrophic response to transverse aortic constriction-induced (TAC-induced) pressure overload, Jmjd2a-Tg mice displayed exacerbated cardiac hypertrophy. We identified four-and-a-half LIM domains 1 (FHL1), a key component of the mechanotransducer machinery in the heart, as a direct target of JMJD2A. JMJD2A bound to the FHL1 promoter in response to TAC, upregulated FHL1 expression, and downregulated H3K9 trimethylation. Upregulation of FHL1 by JMJD2A was mediated through SRF and myocardin and required its demethylase activity. The expression of JMJD2A was upregulated in human hypertrophic cardiomyopathy patients. Our studies reveal that JMJD2A promotes cardiac hypertrophy under pathological conditions and suggest what we believe to be a novel mechanism for JMJD2A in reprogramming of gene expression involved in cardiac hypertrophy.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9148, USA.
authors.forename: Qing-Jun
authors.initials: QJ
authors.lastname: Zhang
authors.forename: Hou-Zao
authors.initials: HZ
authors.lastname: Chen
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: De-Pei
authors.initials: DP
authors.lastname: Liu
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Hill
authors.forename: Zhi-Ping
authors.initials: ZP
authors.lastname: Liu
mesh_terms: D000818:Animals; D001018:Aortic Diseases / Q000150:complications / Q000503:physiopathology; D001483:Base Sequence; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D003251:Constriction, Pathologic / Q000150:complications / Q000503:physiopathology; D005260:Female; D005786:Gene Expression Regulation; D006333:Heart Failure / Q000201:enzymology / Q000209:etiology; D056466:Histone Demethylases / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D006657:Histones / Q000378:metabolism; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D047908:Intracellular Signaling Peptides and Proteins; D056484:Jumonji Domain-Containing Histone Demethylases / Q000235:genetics / Q000502:physiology*; D060588:LIM Domain Proteins; D008297:Male; D008745:Methylation; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009124:Muscle Proteins / Q000096:biosynthesis / Q000235:genetics; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D009687:Nuclear Proteins / Q000502:physiology; D011401:Promoter Regions, Genetic; D011499:Protein Processing, Post-Translational; D034741:RNA, Small Interfering / Q000494:pharmacology; D051381:Rats; D027602:Serum Response Element; D015534:Trans-Activators / Q000502:physiology; D020257:Ventricular Remodeling / Q000235:genetics / Q000502:physiology*; D000099251:Myocardin
chemical_list: D056466:Histone Demethylases; D006657:Histones; D047908:Intracellular Signaling Peptides and Proteins; D056484:Jumonji Domain-Containing Histone Demethylases; D060588:LIM Domain Proteins; D009124:Muscle Proteins; D009687:Nuclear Proteins; D034741:RNA, Small Interfering; D015534:Trans-Activators; D000099251:Myocardin; C486306:Fhl1 protein, mouse; C560307:JMJD2A protein, mouse; C494424:KDM4A protein, human